PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Sequana announces results from study of direct sodium removal

All ten patients involved in the research effectively and rapidly eliminated persistent congestion.

Sequana, a company focusing on liver disease, heart failure, and cancer has announced positive top-line results from SAHARA – the phase 2a study using its first-generation direct sodium removal (DSR) product, DSR 1.0.

Data from ten evaluable diuretic-resistant heart failure patients, with persistent congestion, who also completed a 16-week follow-up period after intensive DSR therapy, confirmed previously reported interim data demonstrating long-lasting clinical benefits.

At baseline, the patients with persistent congestion due to heart failure were on high-dose loop diuretics and had high disease severity. All ten individuals safely, effectively, and rapidly eliminated persistent congestion and achieved euvolemia within one week of commencing intensive DSR therapy, resulting in a mean weight loss of 7kg.

Furthermore, during the intensive DSR period, the diuretic response of the kidney was near-normalised, with the excretion of sodium increasing by more than 160% compared to the baseline. In addition, there was a considerable improvement in cardio-renal health.

Dr. Jeffrey Testani, associate professor at Yale University and heart failure scientific advisor to Sequana Medical, explained: “Congestion is a key driver of heart failure and remains the leading cause of morbidity and hospitalisation in this large and growing patient population. Diuretic resistance is widespread and the usual therapeutic approach is just adding more diuretics, further worsening the underlying issues.

He added: “There are no therapies that seek to correct the cardio-renal pathophysiology causing the diuretic resistance.”

Dr. Oliver Gödje, chief medical officer at Sequana Medical, added: “These results are very positive and reinforce our view that DSR is a potential disease-modifying heart failure therapy. We are excited to have the first patient dosed with DSR 2.0 and we are confident that this second-generation product will deliver important therapeutic and safety benefits.”

To evaluate the safety, tolerability, and efficacy of the company’s second-generation DSR product – DSR 2.0 – a phase 1 study has been initiated in Canada with up to ten patients on peritoneal dialysis receiving a single treatment. Meanwhile, a further phase 1 study is due to take place in Mexico, followed by a randomised phase 1/2a study in the US during 2023.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026